Palmitoylethanolamide

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePalmitoylethanolamide
Drug Alias Name棕榈酰乙醇酰胺Micro-palmitoylethanolamide超微粉化棕榈酰乙醇酰胺Micro-palmitoylethanolamide (micro-PEA) plus pregabalinMicro PEA plus pregabalin +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid receptor agonistsPeroxisome proliferator-activated receptor α agonists
TargetsCannabinoid receptorPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, MajorBipolar Disorder +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEpitech GroupPrismic Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalNavy Medical Center San DiegoPrismic Pharmaceuticals +[6] 
Inactive CompaniesUniversity of California IrvineQuantum BioPharma Ltd
Active IndicationsDepressive Disorder, MajorBipolar DisorderOpioid-Related Disorders +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Tibial FracturesFractures, Bone +[4] 

Other Information

ATC CodeN/A
Related LinksN/A